Half-year report 2023
High-precision delivery
medmix designs, develops, manufactures and delivers innovative high-precision devices and services for the mixing, application and injection of liquids in a wide range of viscosities for the healthcare, consumer and industrial end-markets. medmix shares are listed and traded on the SIX Swiss Exchange in Zurich (Securities No. 112.967.710/ISIN CH1129677105).
Read more about medmix here
Letter to the shareholders
)
Our KEY Figures
248.1 m CHF
revenue in H1 2023
20.0 %
adjusted EBITDA margin
– 4.9 m CHF
free cash flow generated in H1 2023
Financial and business review
)
Financial reporting
)
